At 8.2% CAGR, the Asia Pacific Clinical Trial Imaging Market is projected to be worth US$ 553.11 million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the Asia Pacific clinical trial imaging market was valued at US$ 373.46 million in 2023 and is expected to reach US$ 553.11 million by 2028, registering a CAGR of 8.2% from 2023 to 2028. In-silico imaging clinical trials and AI-driven clinical trials are the critical factors attributed to the Asia Pacific clinical trial imaging market expansion. 

According to a 2023 report by the SPIE, clinical trials are expensive and lengthy, which causes delays in regulatory evaluation and significantly affects patients’ access to novel and high-quality pharmaceutical products. Adoption of in-silico imaging attributes evaluating safety and effectiveness of imaging technologies with less burden than clinical trials as they provide minimal errors. In-silico imaging trials are vital in evaluating new medical imaging systems. Incorporating in-silico trials improved lesion detection performance favoring tomosynthesis for all breast sizes and lesion types. Findings of VICTRE reveal that in-silico imaging trials and computer simulation imaging tools are likely to be viable sources of evidence in the regulatory evaluation of imaging devices, in turn, providing lucrative opportunities for the growth of the Asia Pacific clinical trial imaging market.  

On the contrary, high investment and standardized infrastructure requirements hurdles the growth of Asia Pacific clinical trial imaging market. 

Based on modality, the Asia Pacific clinical trial imaging market is segmented into tomography, magnetic resonance imaging (MRI), ultrasound, positron emission tomography (pet), x-ray, echocardiography, and others. The tomography segment held 38.1% market share in 2023, amassing US$ 142.44 million. It is projected to garner US$ 212.78 million by 2028 to expand at 8.4% CAGR during 2023–2028.

Based on offering, the Asia Pacific clinical trial imaging market is segmented into operational imaging services, imaging software, read analysis services, trial design and consulting services, and others. The operational imaging services segment held 33.1% market share in 2023, amassing US$ 123.57 million. It is projected to garner US$ 181.11 million by 2028 to expand at 7.9% CAGR during 2023–2028.

Based on end user the Asia Pacific clinical trial imaging market is segmented into contract research organizations (CROs), pharmaceutical and biotechnology companies, academic and research institutes, and others. The contract research organizations (CROs) segment held 45.4% market share in 2023, amassing US$ 169.50 million. It is projected to garner US$ 253.20 million by 2028 to expand at 8.4% CAGR during 2023–2028.

Based on country, the Asia Pacific clinical trial imaging market has been categorized into China, Japan, India, Australia, South Korea, and the rest of Asia Pacific.  Our regional analysis states that Germany captured 31.7% market share in 2023. It was assessed at US$ 118.54 million in 2023 and is likely to hit US$ 179.04 million by 2028, exhibiting a CAGR of 8.6% during the forecast period.     

Key players dominating the Asia Pacific clinical trial imaging market are Calyx Inc, eResearch Technology Inc, ICON PLC, IXICO plc, Medical Metrics Inc, Radiant Sage LLC, VIDA Diagnostics Inc, and WCG Clinical Inc among others.   

• In Mar-2023, Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, has announced a partnership with Strados Labs to provide the FDA-cleared RESP Biosensor for clinical trials. This innovative, wearable device is lightweight, comfortable and non-invasive, with capabilities that have not previously existed on the market, such as allowing for objective assessment of crackles, rhonchi, and wheeze events, as well as offering a streamlined approach for at-home cough monitoring in trial participants.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com